Background: Diabetes mellitus (DM) is a syndrome of chronically elevated glucose level in the blood either due to insulin resistance, insulin deficiency or both. In addition, it may occur due to defective metabolism of carbohydrates, fats and proteins. There are 3 main types of DM: Type 2 DM is more prevalent in adults and is typically due to relative insulin deficiency, deficiency of insulin in children leads to DM type 1; and lastly, gestational diabetes occurs during pregnancy resulting from an imbalance of placental hormones. Introduction: Insulin, Biguanides and Sulfonylureas are some of the drug classes used to treat DM. However, their use is complicated by numerous side effects, such as; hypoglycemia & weight gain from insulin and sulfonylureas; lactic acidosis, vitamin B12 deficiency and gastrointestinal upset with metformin. Route of administration and cost are also important factors to consider when prescribing. It is for this reason the quest for newer, safer and easier to administer drugs is ongoing. Methodology: Used all the articles available on anti Diabetic drugs on web especially in British Medical Journal, Elsevier, Pubmed, Google scholar and Wikipedia etc. Got a final review article to compare the older and newer anti Diabetic drugs. Results and Conclusion: Insulin is good for controlling acute hyperglycemic states in DM but it causes acute hypoglycemia and lipodystrophy. Metformin is good hypoglycemic and easily available but causes hypoglycemia, metallic taste, Lactic acidosis and B12 deficiency. Sulfonylureas are good hypoglycemic but causes severe hypoglycemia acutely and weight gain so contraindicated for obese or hypertensive patients. While newer antidiabetics such as GLP 1 agonists increases insulin secretions has very low risk of hypoglycemia, causes weight loss as compared to insulin and decreases risk of cardiovascular side effects but still can’t be used in renally impaired patients, causes pancreatitis and can not be given in gastroparesis patients, similarly a newer drug of this class known as LY2189265 has long halflife of 90 hours, better efficacy, but causes pancreatitis and increase diastolic BP in high doses, pancreatitis is not associated with lixisenatide (GLP 1 agonist), while DPP4 inhibitors which increases GLP 1 in body has less risk of hypoglycemia, GI side effects, are weight neutral can be used in CKD but causes headaches and Nasopharyngitis. Bromocriptine or pegvisomant are used in patients of growth hormones adenoma induced DM as a
References
[1]
Kumar, V., Abbas, A. and Aster, J. (2020) Robbins and Cotran Pathologic Basis of Diseases. 10th Edition, Elsevier, Amsterdam.
[2]
Saeedi, P., Peterson, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., et al. (2019) Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition. Diabetes Research and Clinical Practice, 157, Article ID: 107843. https://doi.org/10.1016/j.diabres.2019.107843
[3]
Centers for Disease Control and Prevention (2018) CDC Statistics of Diabetes in US 2018. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-sta
[4]
Deborah, W. and Ncrna, R. (2019) Insulin Charts. Written by Heather Grey—Updated on March 4, 2019. https://www.healthline.com/health/type-2-diabetes/insulin-chart
[5]
Villa, C., Pan, D., Zaitsev, S., Cines, D., Siegel, D. and Muzykantov, V. (2015) Delivery of Drugs Bound to Erythrocytes: New Avenues for an Old Intravascular Carrier. Therapeutic Delivery, 6, 795-826. https://doi.org/10.4155/tde.15.34
[6]
Tao, L., Vikas, B. and Matthew, S. (2021) First Aid for the USMLE Step 1 2021. 31st Edition, McGraw-Hill Education, New York, 352-353.
[7]
Mcfarthing, K., Larson, D. and Simuni, T. (2020) Clinical Trial Highlights—GLP-1 Agonists. Journal of Parkinson’s Disease, 10, 355-368. https://doi.org/10.3233/JPD-200002
[8]
Andreadis, P., Karagiannis, T., Malandris, K., Avgerinos, I., Liakos, A., Manolopoulos, A., et al. (2018) Semaglutide for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes, Obesity and Metabolism, 20, 2255-2263. https://doi.org/10.1111/dom.13361
[9]
Berlie, H., Hurren, K.M. and Pinelli, N.R. (2012) Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy to Basal Insulin in Patients with Type 2 Diabetes: A Systematic Review. Diabetes, Metabolic Syndrome and Obesity, 5, 165-174. https://doi.org/10.2147/DMSO.S27528
[10]
Htike, Z.Z., Zaccardi, F., Papamargaritis, D., Webb, D.R., Khunti, K. and Davies, M.J. (2017) Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review and Mixed-Treatment Comparison Analysis. Diabetes, Obesity and Metabolism, 19, 524-536. https://doi.org/10.1111/dom.12849
[11]
Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F.E., Nauck, M.A., et al. (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375, 311-322. https://doi.org/10.1056/NEJMoa1603827
[12]
US Food and Drug Administration (2009) MedWatch: The FDA Safety Information and Adverse Event Reporting Program: Safety Information-Byetta (Exenatide)-Renal Failure. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm
[13]
Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373, 2117-2128. https://doi.org/10.1056/NEJMoa1504720
[14]
Clar, C., Gill, J.A., Court, R. and Waugh, N. (2012) Systematic Review of SGLT2 Receptor Inhibitors in Dual or Triple Therapy in Type 2 Diabetes. BMJ Open, 2, Article No. e001007. https://doi.org/10.1136/bmjopen-2012-001007
[15]
Liu, J., Li, L., Li, S., Wang, Y., Qin, X., Deng, K., et al. (2020) Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk of Diabetic Ketoacidosis in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes, Obesity and Metabolism, 22, 1619-1627. https://doi.org/10.1111/dom.14075
[16]
Derosa, G. and Maffioli, P. (2012) Mini-Special Issue Paper Management of Diabetic Patients with Hypoglycemic Agents α-Glucosidase Inhibitors and Their Use in Clinical Practice. Archives of Medical Science, 8, 899-906. https://doi.org/10.5114/aoms.2012.31621
[17]
Bell, D.S., O’Keefe, J.H. and Jellinger, P. (2008) Postprandial Dysmetabolism: The Missing Link between Diabetes and Cardiovascular Events? Endocrine Practice, 14, 112-124. https://doi.org/10.4158/ep.14.1.112
[18]
Yang, H.K., Lee, S.H., Shin, J., Choi, Y.-H., Ahn, Y.-B., Lee, B.-W., et al (2019) Acarbose Add-On Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Diabetes & Metabolism Journal, 43, 287-301. https://doi.org/10.4093/dmj.2018.0054
[19]
Ceppa, E.P., Ceppa, D.P., Omotosho, P.A., Dickerson 2nd., J.A., Park, C.W. and Portenier, D.D. (2012) Algorithm to Diagnose Etiology of Hypoglycemia after Roux-en-Y Gastric Bypass for Morbid Obesity: Case Series and Review of the Literature. Surgery for Obesity and Related Diseases, 8, 641-647. https://doi.org/10.1016/j.soard.2011.08.008
[20]
Standl, E., Schernthaner, G., Rybka, J., Hanefeld, M., Raptis, S.A. and Naditch, L. (2001) Improved Glycaemic Control with Miglitol in Inadequately-Controlled Type 2 Diabetics. Diabetes Research and Clinical Practice, 51, 205-213. https://doi.org/10.1016/s0168-8227(00)00231-x
[21]
Reuser, A.J. and Wisselaar, H.A. (1994) An Evaluation of the Potential Side-Effects of Alpha-Glucosidase Inhibitors Used for the Management of Diabetes Mellitus. European Journal of Clinical Investigation, 24, 19-24. https://doi.org/10.1111/j.1365-2362.1994.tb02251.x
[22]
Ahrén, B. (2009) Clinical Results of Treating Type 2 Diabetic Patients with Sitagliptin, Vildagliptin or Saxagliptin—Diabetes Control and Potential Adverse Events. Best Practice & Research Clinical Endocrinology & Metabolism, 23, 487-498. https://doi.org/10.1016/j.beem.2009.03.003
[23]
Thornberry, N.A. and Gallwitz, B. (2009) Mechanism of Action of Inhibitors of Dipeptidyl-Peptidase-4 (DPP-4). Best Practice & Research Clinical Endocrinology & Metabolism, 23, 479-486. https://doi.org/10.1016/j.beem.2009.03.004
[24]
Scheen, A.J. (2012) DPP-4 Inhibitors in the Management of Type 2 Diabetes: A Critical Review of Head-to-Head Trials. Diabetes & Metabolism, 38, 89-101. https://doi.org/10.1016/j.diabet.2011.11.001
[25]
Drucker, D.J. and Nauck, M.A. (2006) The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes. Lancet, 368, 1696-1705. https://doi.org/10.1016/S0140-6736(06)69705-5
[26]
Amori, R.E., Lau, J. and Pittas, A.G. (2007) Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-Analysis. JAMA, 298, 194-206. https://doi.org/10.1001/jama.298.2.194
[27]
Singh, S., Chang, H.Y., Richards, T.M., Weiner, J.P., Clark, J.M. and Segal, J.B. (2013) Glucagon Like Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus: A Population-Based Matched Case-Control Study. JAMA Internal Medicine, 8, 534-539. https://doi.org/10.1001/jamainternmed.2013.2720
[28]
Gallwitz, B. (2019) Clinical Use of DPP-4 Inhibitors. Front Endocrinol (Lausanne), 10, 389. https://doi.org/10.3389/fendo.2019.00389
[29]
Abrahami, D., Douros, A., Yin, H., Yu, O.H.Y., Renoux, C., Bitton, A., et al. (2018) Dipeptidyl Peptidase-4 Inhibitors and Incidence of Inflammatory Bowel Disease among Patients with Type 2 Diabetes: Population Based Cohort Study. BMJ, 21, Article No. k872. https://doi.org/10.1136/bmj.k872
[30]
Guglielmi, C., Williams, S.R., Del Toro, R. and Pozzilli, P. (2016) Efficacy and Safety of Otelixizumab Use in New-Onset Type 1 Diabetes Mellitus. Expert Opinion on Biological Therapy, 16, 841-846. https://doi.org/10.1080/14712598.2016.1180363
Barrington, P., Chien, J.Y., Tibaldi, F., Showalter, H.D.H., Schneck, K. and Ellis, B. (2011) LY2189265, a Long-Acting Glucagon-Like Peptide-1 Analogue, Showed a Dose-Dependent Effect on Insulin Secretion in Healthy Subjects. Diabetes, Obesity and Metabolism, 13, 434-438. https://doi.org/10.1111/j.1463-1326.2011.01365.x
[33]
Kristensen, S.L., Rørth, R., Jhund, P.S., Docherty, K.F. Sattar, N., Preiss, D., et al. (2019) Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials. Lancet Diabetes & Endocrinology, 7, 776-785. https://doi.org/10.1016/S2213-8587(19)30249-9
